TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02702648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules for oral administration
Study: NCT00278681
Drug: Zinc and ORS
Normalized name: zinc gluconate Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water.
Study: NCT02380677
Drug: CRLX301
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02877615
Drug: S 44819 150 mg twice a day
Normalized name: Horseman's Dream Fung-A-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sachet of S 44819 150 mg and one sachet of placebo twice a day
Study: NCT02877615
Drug: S 44819 300 mg twice a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sachets of S 44819 150 mg twice a day
Study: NCT02877615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sachets of placebo twice a day
Study: NCT00999908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study: NCT00309569
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600mg/m2
Study: NCT00309569
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 40mg/m2
Study: NCT00309569
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 600mg/m2
Study: NCT01945450
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
Study: NCT01945450
Drug: Gentamycin
Normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01945450
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01937182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2-2 tablets per day with no intrinsic drug activity
Study: NCT01681550
Drug: Incretin-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04600895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01747174
Drug: IC Adenosine
Normalized name: Cyclic adenosine monophosphate
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
Study: NCT03591276
Drug: Chemotherapy Drugs, Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
Study: NCT03986294
Drug: S1 + Nal-IRI
Normalized name: IRIS TENAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
Study: NCT03986294
Drug: Nal-IRI+Leucovorin+5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
Study: NCT03431987
Drug: One day with a dose of active THC cannabis paired with alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
Study: NCT00288080
Drug: Oral antiandrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
Study: NCT00288080
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
Study: NCT00608322
Drug: Inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide, 40 parts per million, for six hours.
Study: NCT02933658
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03906123
Drug: NBP
Normalized name: Tri-N-Butyl Phosphate (TNBP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBP soft capsules
Study: NCT03906123
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft capsules manufactured to mimic NBP
Study: NCT02913924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00606281
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 0mg(4tablets)/day
Study: NCT01484912
Drug: STA-2
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
Study: NCT01484912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
Study: NCT04314336
Drug: Drug and Therapeutics Committee
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
Study: NCT01089062
Drug: MAP0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
Study: NCT01089062
Drug: IV Placebo (Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
Study: NCT01089062
Drug: Placebo Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
Study: NCT01969123
Drug: Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01969123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02367183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01175291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
Study: NCT02682901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active placebo for cycloset
Study: NCT03870555
Drug: TAK-954 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-954 placebo-matching infusion intravenous.
Study: NCT02067338
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
Study: NCT03391180
Drug: ICON Remineralization
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A material used for the Remineralization of white spot lesions.
Study: NCT03680105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
Study: NCT00598104
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00598104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01774604
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Indomethacin PR x 1
Study: NCT01774604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04446000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution matching the excipient profile of CSL730 without the active substance
Study: NCT04382339
Drug: SOF/RBV/PegINFα-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
Study: NCT03492138
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625mg
Study: NCT00119106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04379024
Drug: DUAVEE 0.45Mg-20Mg Tablet
Normalized name: DUAVEE 0.45mg-20mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule daily for 6 months (+/- 1 month)
Study: NCT04476069
Drug: IBUPROFEN
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given to children 30 minutes before extraction / orally for one time only
Study: NCT03469375
Drug: modified-FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
Study: NCT01053585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single 'dose' 90 minutes prior to study
Study: NCT00790985
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiinflammatory drug
Study: NCT02809937
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline infusion
Study: NCT03470441
Drug: FDY-5301
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
Study: NCT04564937
Drug: SCT510A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
Study: NCT00440219
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill identical to Prednisone 10 days once daily pre-op
Study: NCT04345107
Drug: SY-009 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-009 matching placebo
Study: NCT00525213
Drug: Rob 803
Normalized name: CATHETER,ROB-NEL 20FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: two capsules per day during 12 weeks
Study: NCT00525213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two capsules per day during 12 weeks
Study: NCT00000245
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04168398
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation
Study: NCT00096070
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00801632
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg infusion on days -5, -4
Study: NCT00474513
Drug: GSK239512
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03454620
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1118 combination with FOLFIRI
Study: NCT00937196
Drug: Placebo globuli
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo globuli administered together with verbal suggestions of a hypotensive drug effect
Study: NCT00392041
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill qpm for 12 weeks
Study: NCT02272270
Drug: Minocycline with chemoradiation (temozolomide and radiation therapy)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
Study: NCT00801632
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
Study: NCT04243681
Drug: Standard of care for Cirrhosis management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
Study: NCT01452828
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two separate infusions of 200 mg
Study: NCT01452828
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion, 200 mg daily for 7 days
Study: NCT03198208
Drug: Fentanyl dose administration
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02693587
Drug: Misodel and Angusta
Normalized name: Laminaria angustata extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00615823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
Study: NCT00730405
Drug: Placebo 400 mg
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 36 weeks
Study: NCT03851705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% sodium chloride in water for injection)
Study: NCT03851705
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% sodium chloride in water for injection)
Study: NCT00796198
Drug: Xalatan+Cosopt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
Study: NCT00821353
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
Study: NCT00216736
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral placebo at ED discharge
Study: NCT00857038
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline tablets, 100mg daily
Study: NCT00857038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 100mg
Study: NCT01191398
Drug: Normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
Study: NCT03815305
Drug: Topical CA
Normalized name: Topical Cake
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% centella asiatica ointment
Study: NCT00230737
Drug: Melatonin 0.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00230737
Drug: Melatonin 4.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00230737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00440505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
Study: NCT00836485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control is a placebo patch that contains only the inactive ingredients of ketotifen.
Study: NCT00158158
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: If unable to quit at quit date, offered usual care to set another quit date.
Study: NCT02128308
Drug: Levofloxacin and Streptomycin added
Normalized name: streptomycin and isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02128308
Drug: Moxifloxacin and Kanamycin added
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00887757
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study: NCT02351700
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo intraoperatively and postoperatively
Study: NCT00838136
Drug: Lamictal® 25 mg Chewable Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 25 mg, single-dose fed
Study: NCT00841542
Drug: Norvasc®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Tablet
Study: NCT00217763
Drug: 3APS
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02307994
Drug: 75IU uFSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02027337
Drug: 20 mcg ethinylestradiol /3 mg drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
Study: NCT03954600
Drug: Placebos (125 mg)
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 125 mg oral capsules
Study: NCT00135122
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
Study: NCT02925494
Drug: Estradiol/Norethindrone Acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT01462266
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to sitagliptin once daily for 24 weeks
Study: NCT02027337
Drug: 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit
Approvals — FDA: no, EMA: no, PMDA: no
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Study: NCT02027337
Drug: 30 mcg ethinylestradiol/3 mg drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
Study: NCT02027337
Drug: 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit
Approvals — FDA: no, EMA: no, PMDA: no
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Study: NCT00483730
Drug: Deproteinised hemoderivative of calf blood (Actovegin)
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic diabetic peripheral polyneuropathy
Study: NCT00941785
Drug: DHA-PQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days
Study: NCT00941785
Drug: SP-AQ
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg
Study: NCT02027337
Drug: 35 mcg ethinylestradiol/2 mg cyproterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
Study: NCT01680900
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules matched to drug capsules.
Study: NCT01915082
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
Study: NCT01915082
Drug: Ora-Plus
Normalized name: Ora-Plus Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
Study: NCT04348409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo BID for 7 days
Study: NCT05683444
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Infusion
Study: NCT00398463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion will be administered for 14-24 hours
Study: NCT02027337
Drug: 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
Approvals — FDA: no, EMA: no, PMDA: no
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Study: NCT00898560
Drug: Microginon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
Study: NCT00318760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule 1 dose
Study: NCT02482129
Drug: LME636 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used for masking purposes